Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Eisai, UCL commence phase I clinical studies for anti-tau monoclonal antibody

expressbpdDecember 10, 2018

Tag: Eisai , UCL , monoclonal antibody

PharmaSources Customer Service